Phaseline

Companies › Cothera Bioscience

Cothera Bioscience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sepantronium Bromide (PC-002)
BCL2 inhibitor
BCL2Phase 2High-grade B-cell Lymphoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05263583Sepantronium Bromide (PC-002)Phase 2High-grade B-cell LymphomaOncologyFeb 2025

Targets

BCL2 (1)

Companies with the same targets

Ascentage Pharma Group AbbVie BeOne Medicines Bio-Path Holdings BeiGene Shanghai Fosun Pharmaceutical Industrial Development Lomond Therapeutics Holdings Guangzhou Lupeng Pharmaceutical Company

Companies built like this

NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.